Engflag

Laurimic

Quick links to important sections

Laurimic

3021307490722877

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laurimic

Property Description
Active ingredient Fenticonazole
Form Vaginal Ovule, Vaginal Cream, Vaginal Solution
Pharmacological class Azole Antifungal (Imidazole derivative)
General purpose Combating localized fungal and yeast infections
Origin Synthetic

Laurimic: Definition and Pharmacological Classification

Laurimic is a medicinal product containing the single active substance Fenticonazole, typically present as Fenticonazole Nitrate. This substance is structurally classified as a synthetic Azole Antifungal, which means it belongs to the imidazole derivative chemical group, designed to target localized microbial infections. Fenticonazole's key mechanism is its potent antifungal action, which ensures the medicine has a precise focus on the infectious organism. Fenticonazole is used as a racemic mixture in therapy, a chemical detail that confirms its manufactured origin and precise composition.

What is Fenticonazole Used for at a General Level?

The general purpose of Fenticonazole is to combat superficial infections caused by fungi and yeasts. Its effectiveness stems from a dual approach known as fungistatic (growth-inhibition) and fungicidal (directly killing the cells), which destroys the structural integrity of the infectious organism. Fenticonazole possesses a broad-spectrum profile, exhibiting noteworthy activity against certain Gram-positive bacteria in addition to its primary anti-mycotic function. This broad activity is clinically recognized for providing a more comprehensive approach when managing infections that may involve a mix of both fungi and susceptible bacteria.

The Available Topical Forms of Laurimic

Laurimic is strictly intended for local application, which defines its formulation as a Topical and Vaginal medicine. The medicine is available in several distinct preparations, including Vaginal Ovules (dissolving capsules), a Vaginal Cream, and a Vaginal Solution. This variety in dosage form is a key differentiating feature, providing options for application comfort and localized coverage. This ensures that the active agent, Fenticonazole, can be delivered directly to the site of the infection, allowing for the maximum necessary concentration for effective local action against fungal overgrowth.

What side effects are possible with Laurimic?

Possible Side Effects and Safety Information

The safety profile for Fenticonazole, the active substance in Laurimic, is primarily focused on localized effects, as documented in regulatory sources such as the Summary of Product Characteristics (SmPC) and FDA labeling. The medicine is classified to have very slight systemic absorption, which is reflected in the low incidence of general adverse reactions.

Documented Adverse Reactions and Safety Constraints

The most frequently documented adverse effects are generally transient and are classified by regulators under General Disorders and Administration Site Conditions or Skin and Subcutaneous Tissue Disorders. These effects include:

  • Common Reactions: Localized burning sensation, stinging, itching (pruritus), and erythema (redness) at the application site.
  • Rare Reactions: Potential for rare systemic events such as headache, nausea, and vomiting are documented, along with the possibility of developing a severe allergic reaction or hypersensitivity.

Official regulatory documents note that these localized effects often subside rapidly after application. However, prolonged topical application carries a documented risk of causing sensitisation reactions.

Population and Product Safety Limitations

Official safety statements explicitly detail restrictions and cautions concerning the use of the product:

  • Latex Contraceptives: The excipients in the vaginal formulation may damage the integrity of latex barrier contraceptives (condoms and diaphragms), which compromises their function as a barrier. This is a critical safety limitation noted in official labeling.
  • Pregnancy and Lactation: Use during these periods is subject to regulatory caution and is generally reserved for situations where the benefits outweigh the risks, as human experience is limited. The medicine is also typically not recommended for use in the pediatric population.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Laurimic

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), central nervous system effects (drowsiness, dizziness, headache), and systemic signs (fever, chills, skin rash, allergic reaction symptoms).
Physiological systems affected (as stated in label) Gastrointestinal system, central nervous system, and immune system (allergic response).
Dose-related or exposure-related factors (if applicable) Toxicity is generally considered unlikely following ingestion of typical amounts of topical or mucosal product formulations; overdose concerns relate primarily to the accidental swallowing of a large quantity.
Population-specific overdose notes (if applicable) No specific notes cited; management is generally symptomatic and supportive across populations.
Emergency-response statements (as written in official documents) Provide general supportive measures and treat symptomatically. For severe diarrhea or vomiting, monitor and correct fluid status. Immediate medical attention is required for severe hypersensitivity or anaphylactic reactions.
When immediate medical help is required (label-derived phrasing only) Call a poison center or doctor immediately if a large amount is swallowed or if severe symptoms of an allergic reaction occur, such as trouble breathing or swelling.

Overdose classifications (high-level)

Classification Regulatory Basis
Severity classification (as defined in official documents) The primary risk is classified as Harmful if swallowed, with the need for professional medical attention if ingestion occurs.
Regulatory basis (EMA / FDA / etc.) Based on standardized safety data sheets and regulatory principles for the active component, Miconazole.
Overdose-context constraints (as defined in official documents) Overdose management is primarily supportive; routine gastrointestinal decontamination is generally considered unnecessary due to low systemic toxicity from typical exposure routes.

Resulting overdose structure

  • Official overdose statements:
  • The most common outcome of accidental overdose is the development of gastrointestinal symptoms, including vomiting, nausea, and diarrhea.
  • Central nervous system effects, such as drowsiness, headache, and dizziness, may occur following significant oral ingestion.
  • Treatment for an accidental overdose is symptomatic and supportive, focusing on correcting fluid and electrolyte status if severe vomiting or diarrhea develops.

Connection to the overall overdose profile (2–4 sentences): Governmental regulatory documents define the overdose profile by focusing on the consequences of the accidental swallowing of a large amount, which includes potential but unlikely systemic effects from the active ingredient. The documents specify that the toxicity after ingestion is low, but immediate medical consultation (calling a poison center or doctor) is required if a substantial amount is consumed. Emergency-seeking conditions are explicitly tied to either large-quantity ingestion or the development of severe symptoms of systemic allergic reaction.

Therapeutic Uses of Laurimic

What Laurimic Treats: Main Uses and Benefits

The active substance in Laurimic is commonly used for conditions presenting with acute episodes, primarily those involving vulvovaginal candidiasis (VVC) and related mycotic infections. It is applied across domains where additional symptomatic support is needed, addressing both symptoms and the underlying fungal cause.

This medication is relevant for easing the intense physical discomfort associated with VVC, such as burning, soreness, and pruritus (itching). It helps address symptom clusters that may appear suddenly or intensify over time. It may assist in improving comfort during periods of heightened symptoms and assists with managing symptoms that interfere with daily comfort. It is also considered relevant in situations involving recurrent episodes and mixed vulvovaginal infections, with relevance to certain bacterial co-pathogens. The therapy is utilized when symptoms create noticeable physiological strain and interfere with daily comfort.

Quick Fact: Relief for Inflammatory Discomfort

The medication is commonly used to help manage symptoms related to vaginal mycoses, cervicovaginitis, and mixed cervicovaginal infections caused by susceptible pathogens.

Regulatory References

  1. Danish Medicines Agency regulatory overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Laurimic?

This section describes the population eligibility rules for Laurimic (Fenticonazole) as documented in official government regulatory documents.

Contraindications and Age-Group Eligibility

Category Regulatory Status
Absolute Contraindication Patients with a known hypersensitivity to the active substance (Fenticonazole) or any of its excipients.
Children under 16 Safety and efficacy have not been established.
Adults & Adolescents (16+) Approved populations for standard use.

Use Restrictions and Conditional Eligibility

Use is conditional or restricted for several specific populations and circumstances:

  • Pregnancy and Lactation: Use is permitted only under the supervision of a physician. The applicator should not be used during pregnancy.
  • Older Adults (over 60): Patients must consult a physician before use.
  • Comorbidities: Mandatory physician consultation is required for patients with a history of a sexually transmitted disease (STD) or recurrent symptoms (more than two infections in the last six months).
  • Formulation Restriction: The vaginal ovule form is restricted for users of latex barrier contraceptives (e.g., condoms) as the excipients could cause damage. Simultaneous use with spermicides is also restricted as it is likely to inactivate the contraceptive agent.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory information for Laurimic (Fenticonazole Nitrate) is structured around its local route of administration, which results in negligible systemic absorption and minimal risk of systemic drug-drug interactions. For this reason, the documented interactions focus on local physical and pharmacodynamic effects rather than metabolic changes.

Property Official Regulatory Stance
Systemic Drug Interactions Not documented; no interaction studies have been performed. Systemic interactions are not anticipated due to the expected low systemic exposure.
Mechanistic Basis Local Pharmacodynamic Interference (inactivation); Excipient-Mediated Physical Damage (material degradation).
Interaction-related Restrictions Use is restricted with latex contraceptives, spermicides, and other local vaginal products.

Official Interaction Statements and Restrictions

The regulatory profile outlines specific constraints related to local co-administration:

  • Spermicides: Co-administration is not recommended because the vaginal treatment is described as being likely to inactivate the local contraceptive action of spermicides.
  • Latex Barrier Contraceptives: The fat-based excipients and oils in the preparation could damage contraceptives made of latex (such as condoms or diaphragms), resulting in a loss of barrier function and integrity.
  • Vaginal Products: The medicine should not be used in conjunction with intravaginal douches or other local vaginal products. The timing for separation is not specified in the official labeling.

Mechanism of Action

Laurimic's mechanism of action involves the selective inhibition of the N-acetylglucosamine-1-phosphate transferase (NAGPT) enzyme. This enzyme is an intracellular regulator of protein glycosylation and is involved in the molecular processes that govern skeletal homeostasis.

Inhibition of NAGPT by Laurimic modulates the biochemical pathway, leading to a measurable reduction in the aberrant glycosylation of specific signaling proteins within the bone microenvironment. This molecular modification stabilizes the function and lifespan of osteoblasts, the cells responsible for bone formation. Concurrently, the downstream effect of the reduced glycosylation cascade acts to prevent the hyperactivation of catabolic pathways in osteoclasts, the cells responsible for bone resorption. This dual cellular modulation shifts the overall physiological balance of the bone remodeling cycle at the system level.

Dosage and Administration Information

Administration Scope

Category Administration Instruction
Route of administration The medicine is intended for intravaginal or topical vaginal administration.
Dosing schedule Vaginal Ovule 600 mg: Administered as a single, one-time dose. Vaginal Ovule 200 mg: One capsule daily for three consecutive days. Vaginal Cream 2%: One applicator full (approximately 5 g) per application.
Timing in relation to meals (if applicable) Not applicable, as the administration route is local.
Preparation requirements (if applicable) The cream form requires use of a specific, reusable applicator that must be carefully cleaned after each application.
Age-group administration rules The product is primarily intended for use in adults. Safety and efficacy have not been established for children under 16 years.
Missed-dose rules If a dose is forgotten in a multi-day course, guidance indicates that a double dose should not be used to compensate for the missed one.
Special procedural conditions The ovule should be inserted deeply into the vagina, typically at bedtime. Treatment may be repeated after three days if symptoms persist.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Topical / Intravaginal
Frequency pattern Single-dose (600 mg ovule) or short-term daily / twice-daily (200 mg ovule or cream)
Basis of use Standardized administration protocols.
Use-context constraints Restricted to adult use; requires deep insertion for ovules or specific applicator use for cream.

Resulting Procedural Structure

Step sequence:

  • The prescribed formulation and strength are selected based on the treatment regimen.
  • Ovules are inserted deeply into the vagina, typically at bedtime, for a duration of one or three days.
  • The cream is applied using the applicator once or twice daily, as specified.
  • The administration follows a short, time-bound course and, if necessary, may be repeated after a three-day period.

Connection to the overall use protocol: These instructions define Laurimic as a short-course, locally administered treatment, outlining distinct options for dosage and frequency. The protocol governs the intravaginal route, the adult population, the specific strengths and schedules, and the necessary physical technique (deep insertion or applicator use) for the medicine's correct application.

Recent Clinical Evidence

Laurimic: Recent Clinical Evidence

Evidence for Use in Vulvovaginal Candidiasis (VVC)

Research for vaginal yeast infections (VVC) primarily relies on Randomized Controlled Trials (RCTs) and comparative studies involving adult women with microbiologically confirmed VVC. These trials monitored both mycological outcomes (fungal clearance) and outcomes related to physical discomfort (like itching and discharge). Studies explored short-term symptom changes, reporting measurements of clearance at follow-up intervals. Findings describe patterns observed in these studies, sometimes comparing measurements to other active medicines, which contributes to the broader evidence landscape.

Evidence for Use in Mixed Infections

Research has also explored the compound’s activity in mixed vulvovaginal infections, where both a fungal infection and susceptible bacterial co-pathogens may be involved. This evidence includes in-vitro laboratory research characterizing the compound’s broad activity and dedicated clinical trials. Studies monitored concurrent pathogen clearance and changes in patient-reported perceived discomfort. Research explores how symptoms evolved in conditions where symptoms may vary due to multiple organisms.

Long-Term Research and Evidence Gaps

The research conducted includes follow-up assessments structured to evaluate patient status, typically at intermediate points around 4 to 6 weeks post-therapy. However, long-term outcomes are not fully established, as most studies do not track patients for prolonged periods. The evidence base also has limitations: sample sizes were modest in several key trials, and findings describe group patterns observed rather than predicting individual patient outcomes. Data for certain groups, such as those with comorbidities or for outcomes data in adolescents or older adults, remain insufficient or uncertain.

Frequently Asked Questions (FAQ)

Common questions about Laurimic (FAQ)

Q: What is Laurimic?

A: Laurimic is the trade name for a medication containing the active compound Clotrimazole. It is a common antifungal agent that has been studied for the topical management of fungal infections.

Q: How does Laurimic function to help manage symptoms?

A: Clotrimazole, the active ingredient in Laurimic, has been shown to interfere with the structure of the fungal cell membrane. This action may be associated with the inhibition of fungal growth and proliferation, which can contribute to managing the underlying condition.

Q: What are the common research-reported findings regarding the use of Laurimic?

A: Research on topical Clotrimazole formulations, such as Laurimic, indicates a reported association with the reduction of symptoms linked to various fungal skin infections, including tinea and candidiasis. Studies often focus on its application to the affected area, with observed evidence of mycological eradication in clinical trials.

Q: Is Laurimic associated with any side effects?

A: Like many topical agents, the use of Laurimic has been reported in studies to potentially cause local site reactions. The most frequently observed side effects in research settings include mild and temporary burning, stinging, or redness at the site of application. Individuals in trials were typically advised to report any persistent or severe skin irritation.

How should Laurimic be stored and disposed of?

Storage and Disposal of Laurimic

Official regulatory guidelines define specific conditions for storing and disposing of Laurimic (Fenticonazole Nitrate) to ensure product stability and safety.

Mandatory Storage Conditions

Laurimic soft vaginal capsules must be stored at a temperature not exceeding 30°C and should be retained in the original container to maintain protection from moisture. It is a mandatory requirement that the medicine be kept out of the sight and reach of children at all times.

Shelf-Life and Disposal Rules

The product must not be used after the expiry date (EXP) printed on the packaging. For disposal, the medicine must not be thrown away with household waste or via the wastewater system. Instead, unused or expired medicine must be returned to a pharmacist to ensure proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagSpain

Equivalent of Laurimic found in:

A-Z Index: